Core Viewpoint - The announcement from Innovent Biologics regarding the acceptance of the marketing application for its drug, Isemepitide, represents a significant advancement in obesity treatment options in China, potentially providing a new effective and safe choice for patients with moderate to severe obesity [1] Group 1: Company Developments - Innovent Biologics' stock rose over 4%, reaching HKD 98, with a trading volume of HKD 405 million [1] - The marketing application for Isemepitide (9mg) has been accepted by the National Medical Products Administration (NMPA) in China, targeting long-term weight control in adults with moderate to severe obesity [1] - The application is based on the successful results of the Phase III clinical study GLORY-2, which met all primary and key secondary endpoints [1] Group 2: Product Information - Isemepitide is the only GLP-1 class drug that can achieve over 20% weight loss after one year of treatment through a two-step dose titration [1] - The drug aims to provide evidence-based medical support for effective weight management in moderate to severe obesity patients, beyond surgical options [1]
港股异动 | 信达生物(01801)涨超4% 玛仕度肽注射液高剂量9mg上市申请获受理